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Abstract 
 
Objective To assess whether fertility was possible following allogeneic uterine transplantation 
(UTn), whereby the recipient had demonstrated long-term survival and had been administered 
immunosuppression. 
Design  Case series. 
Setting  Royal Veterinary College, London, UK and Institute of Science and Animal 
Technology, Valencia, Spain. 
Population 18 New Zealand white allogeneic rabbit does of proven fertility were used as donor 
and recipient animals (nine donors, nine recipients). 
Methods Nine allogeneic UTn in the rabbit model were performed using a pre-determined 
protocol. Embryos were transferred into each cornua via a mini-midline laparotomy. The pregnancy 
was monitored with regular reproductive profiles and a colour Doppler ultrasound to measure fetal 
growth. 
Main Outcome Measures Presence of conceptus, size and growth of fetus, markers of acute 
rejection, biochemical reproductive, renal and hepatic profiles. 
Results  Recipient #5 was the sole surviving doe out of the cohort of nine. Day 5 post-embryo 
transfer (D5) scan did not demonstrate a fetal sac. Fetal sac diameter on D9, D13, D16 and D18 was 
(mm): 17.3x13.1, 22.1x19.5, 25.2x22.7, and 10.2x6.3. Crown-rump length was only recordable on 
D9, D13 and D16. Subsequent scans on D22 and D25 did not demonstrate a fetal sac, which together 
with the fetal sac diameter was suggestive of resorption. The recipient was sacrificed on D27. 
Necropsy and histopathology confirmed evidence of a gravid uterus and presence of a gestational sac. 
Conclusions Despite the end result of the experiment i.e. termination of pregnancy as a result of 
miscarriage, the study represents only the third example of conception and pregnancy following an 
allogeneic UTn. 
Key Words Fertility, Uterine Transplantation, Rabbit, Pregnancy 
Abstract Word Count   254 
Manucript Word Count  4414 
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Introduction 
 
Uterine transplantation (UTn) has been proposed as a treatment option for women diagnosed with 
absolute uterine factor infertility (AUFI) and who are willing to bear their own child.1 AUFI renders a 
woman ‘unconditionally infertile’. Causes are congenital, such as Mullerian duct anomalies, or 
acquired (for example, a hysterectomy performed secondary to obstetric haemorrhage, myoma, 
endometrial or cervical malignancy). Since the first human UTn attempt in 2000 in which the donor 
graft failed after 99 days because of thrombosis of the uterine vasculature leading to subsequent 
necrosis of the transplanted uterus, important advances have been made into several fields which 
define UTn. These include donor graft retrieval, minimisation of ischaemic-reperfusion and 
allorejection-related injury, optimisation of surgical techniques to allow for an adequate uterine blood 
supply, and finally achieving the ‘Holy Grail’ of UTn: pregnancy and a live birth of a healthy neonate 
following allogeneic UTn (Figure 1).2  
 
The Brannstrom group has described five examples (three murine and two rat models) of successful 
pregnancy post-UTn. The first example in 2002 consisted of a syngeneic transplantation of the right 
uterine horn and cervix, with the native uterus remaining in situ and subsequent successful fertility 
following blastocyst transfer and implantation in a single mouse model. The mouse was 8 weeks old, 
with the embryo transfer occurring one week post-UTn. This proved, for the first time, the concept of 
pregnancy following a uterine transplant in a non-autotransplant model. The aim of the authors was to 
assess the macrovascular anastomotic model previously described; the pregnancy experiment was a 
secondary aim.3  
 
The second example of pregnancy post-UTn was in fact a pregnancy-related study.4 It was an 
extension of the above study with the focus on pregnancy-related factors. Transplantation of one 
uterine horn was performed in a syngeneic mouse model that used a macrovascular anastomosis 
concept to ensure uterine perfusion. Embryos were transferred 1-3 weeks post-UTn in both the 
transplanted and native uteri. The embryo preparation was as per standard mouse protocols.519 mice 
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received a transplanted uterus. Out of those, 12 had viable grafts and thus received an embryo. 
Pregnancies were found in nine of 12 native uteri of transplanted mice and in those nine, eight also 
had fetuses within the transplanted uterus. With respect to the controls, eight out of 13 mice were 
pregnant. The lengths and weights of the fetuses, as well as weights of the placentae, were similar in 
pregnancies in native, grafted and the ‘control’ uteri. The placental aspect should be highlighted as the 
data may be extrapolated to the human model. In this experiment, UTn did not compromise placental 
development. Offspring from all three groups followed a similar post-natal growth pattern until eight 
weeks of age. They were then tested to see if they could continue the progeny. Both female and male 
offspring proved to be fertile and the pups reported birth weights within the normal range. Therefore, 
the experiments demonstrated similar implantation and pregnancy rates, as well as birthweight and 
growth curves (8 weeks) between the native and transplanted (syngeneic) uteri. The second-generation 
offspring from transplanted animals were all fertile with normal birth weights.4   
 
However, the above murine experiments still differ somewhat from a human model. Three areas in 
particular are immediately obvious: gestational lengths, no immunological rejection mechanisms to 
consider and anatomical differences. The following experiments tried to counter some of these 
differences. In October of 2010, the Brannstrom group described the first recorded pregnancy in an 
allogeneic uterine transplant (rat model). It is therefore a central proof of a concept that a uterus can 
function following its transplantation from a donor to a recipient and that it can do so under 
immunosuppression.6  
 
Their next experiment was also an advancement on the existing work - again a rat model, but with an 
attempt to bring about pregnancy following natural mating.7 Furthermore, the actual transplant was 
orthotopic for the first time i.e. the native uterus was removed and the graft was placed in lieu. Female 
Lewis rats underwent hysterectomy and received syngeneic uterine transplants (with one horn 
removed). The uterine graft was placed in an orthotopic position i.e. in the pelvis with two tissue 
anastomoses: to the vagina and the upper part of the native uterine horn. The anastomosis was end-to-
side between the common iliac vessels of the recipient and the graft. Control rats had only one uterine 
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horn removed. The overall pregnancy rates after introduction to male rats were comparable in UTn 
(11/19; 58%) and control (12/19; 63%) rats. From the UTn rats, only one rat delivered two healthy 
male pups. Two other UTn rats gave birth to at least two pups each but committed infanticide prior to 
the offspring count. The weight and development outcomes post-birth for the two surviving male rat 
pups from the one UTn rat were similar to the control rat offspring (32 live born pups). The main 
differences between the UTn and control groups were the increased number of resorptions and 
decreased number of successful deliveries in the former group. Thus, some unknown factor is 
compromising fetal wellbeing post-UTn, most likely blood flow or denervation. In the control group, 
no nerve manipulation occurred and there were no issues with labour. Also vaginal scarring at the 
anastomosis may cause a synthetic obstruction to the labour pathway. Obviously in future models, 
both animal and human, elective Caesarean section would remove these obstacles. In conclusion, this 
model may be reproduced to assess fertility outcomes following allogeneic UTn and ensuing natural 
mating. The study demonstrates that conception by natural mating, and subsequent pregnancy, and 
birth of live and healthy offspring is possible with orthotopic, syngeneic UTn.7  
 
Transplant Immunology and Pregnancy 
 
Today, immunosuppressants are routinely used after transplantation to minimize the risk of rejection. 
However, long-term use has its drawbacks, mainly the risk of recurrent infections and neoplastic 
disease, as well as necessary close and meticulous medical care.8 UTn would be short term i.e. 2-4 
years thus avoiding this risk.  Once the uterus and immunosuppressants are removed, any associated 
neoplasm risk should theoretically return to baseline. Many transplant related lymphomas are known 
to regress after removal of the graft.  
 
Nevertheless, care is taken with the type, dose and monitoring of immunosuppressants prescribed as 
they can cross the human placental barrier and enter the fetal circulation, possibly affecting the 
immune system of the fetus.9 Medications used to suppress immunologic activity are summarised in 
Table 1. McKay and Josephson have summarised the outcomes of approximately 14000 post-
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transplantation live births since the first birth to a transplant recipient occurred in 1963.10 Therefore, 
the stratification of immunosuppressants is necessary as observations on post-transplant pregnancies 
indicate a higher incidence of preterm deliveries, low birth weights, and maternal hypertension but no 
increased rate of structural malformations.11-14 
 
Nevertheless, we must acknowledge that long-term data on allograft loss, maternal survival after 
pregnancy (due to an increased risk of viral diseases and neoplasm secondary to 
immunosuppressants)15 and offspring outcomes of transplant recipients is rather limited. Despite 
several reports indicating no increase of congenital anomalies among the offspring of recipients,14,16 
long-term outcomes focusing on physical and mental development, and immunological and 
oncological pathologies later in life in these offspring is necessary.17 Unfortunately, currently, only 
one study has compared pregnancy outcomes in a single group of women before and after 
transplantation. It concluded that despite an initial increased risk for pre-eclampsia, growth restriction, 
pre-term birth, and the risk of miscarriage, the odds of these four outcomes were all statistically 




The aim in this study was to assess whether fertility (conception, pregnancy and fetal well-being) was 
possible following orthotopic, allogeneic UTn, whereby the recipient had demonstrated long-term 
survival and had been administered immunosuppression. 
 
Materials and Methods 
 
The feasibility of the uterine allograft dissection together with its vascular supply that includes the 
internal and common iliacs, the abdominal aorta (AA) and the inferior vena cava (IVC) was first 
ensured by a series of uterine transplantations in the rabbit model performed by this team.19 Here, we 
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performed two surgically explorative procedures and nine allogeneic uterine cross transplantations in 
the rabbit model using a pre-determined protocol. 
 
18 New Zealand white rabbits were used as donor and recipient animals (nine donors, nine recipients). 
They were all allogeneic does of proven fertility with at least one previous litter each. The animals 
were acquired a few days before the operation to ensure appropriate acclimatization to their 
surroundings. 
 
This particular surgical procedure has already been described in detail.19,20 The uterine allograft along 
with the AA, IVC, common and internal iliacs, and uterine arterial and venous tree all intact were 
retrieved en bloc.  
 
Rabbit embryo preparation 
 
The protocol was prepared by the rabbit fertility team of the Polytechnic Institute, Valencia, Spain, led 
by Professor Jose Vicente. Sixty hours before insemination time, superovulation was induced in  nine 
donor does following subcutaneous injection of 20IU/kg of eCG (Gonaser, Hipra, S.A.). Ejaculates 
from five proven males were collected using an artificial vagina. A 10µL aliquot samples 
from ejaculates were diluted 1:10 with Tris-citrate-glucose extender (250mM tris-
hydroxymethylaminomethane, 83mM citric acid, 50mM glucose, pH 6.8-7.0, 300 mOsmkg-
1) for a previous motility rate evaluation. Ejaculates with an estimated motility higher than 
70% were pooled. From ejaculates, two aliquot sample of 10µL were taken, the first one was 
diluted 1:10 with Tris-citrate-glucose extender for motility rate evaluation in a computer 
assisted sperm analysis (CASA) system and the second one was diluted 1:10 with 1% of 
glutaraldehyde solution in phosphate buffered saline to calculate the concentration in a 
Thoma chamber and to evaluate both the percentages of normal intact acrosome and 
abnormal sperm by phase contrast at a magnification of x400. Only ejaculates with more than 
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70% of motility rate, 85% of normal intact acrosome, and less than 15% of abnormal sperm 
were pooled and used to inseminate donor does. Pooled semen was diluted to 40 million per 
milliliter adding Tris-citrate-glucose extender in order to elaborate the seminal doses.  Donors 
were inseminated with a seminal dose of 0.5 ml..  
 
Ovulation was induced in the donor does immediately after insemination by an intramuscular injection 
of 2µg of Buserelin Acetate (Hoechst, S.A.). The embryos were recovered in vivo by ventral midline 
laparoscopy 76-78 hours after the insemination, according to the method described by Besenfelder et 
al.22 First, anaesthesia was induced by an intramuscular injection of 16mg xylacine (0.8ml of 
Rompun; Bayer AG, Leverkusen, Germany), followed by an intravenous reinjection of ketamine 
chlorohydrate (Imalgene; Merial, S.A., Lyon, France) to maintain does under anaesthesia during 
laparoscopy. Rabbit donor does were placed in a head-down position at a 45ºC angle. A Verres needle 
was inserted in the lower right abdominal quadrant and attached to CO2 automatic insufflator. After 
CO2 abdominal distension, a trocar-cannula unit of 5mm diameter was inserted into the abdominal 
cavity at 10cm caudal to the sternum. Another accessory (3mm diameter) trocar-cannula unit was 
inserted 4-5cm laterally to right of the former. After both were removed, they were respectively 
replaced by the laparoscope (Wolf paediatric 0º) and grasping forceps (length: 28.5cm). Subsequently, 
an epidural needle (inner diameter: 1mm, Vigor Epidural G17) was inserted near the ovary and a 
sterile polyethylene tube (inner diameter: 0.3 mm) attached to a 5ml sterile syringe was introduced for 
2-3cm through the epidural needle into the oviduct. After fixation with the grasping forceps, ova and 
embryos were flushed from the oviducts to uterine horns with 5ml of Dulbecco´s phosphate buffered 
saline (DPBS, Sigma) containing 0.2 %  (w/v) of Bovine Serum Albumin (BSA, Sigma) and 
supplemented with antibiotics (200 IU/mL penicillin G and 0.25mg/mL dihydrostreptomycin; Penivet 
1). This was followed by flushing of the uterine horns, elevated with the grasping forceps placed near 
the oviduct-tube junction, with 50ml of the same flushing solution. It was achieved via insertion of a 
sterile epidural needle directly through abdominal wall into each uterine horn. Finally, the recovery 
medium was aspirated from the vagina by a Foley Catheter (Minitube, Tiefenbach, Germany) 
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connected with a vacuum pump of 20-40mmHg. After the recovery of does, the reproductive tract was 
washed with 0.1% ethylenediaminetetraacetic acid solution in PBS in order to prevent any abdominal 
adhesions post-laparoscopy.  
 
In both groups, recovered embryos were scored by morphological criteria. Only embryos in the 
morula stage with homogeneous blastomeres as well as a visible regular mucin coat and zona 





Vitrification and thawing process 
 
All normal embryos (morulae) were vitrified by the methodology described by Vicente et al.193 
Briefly, the vitrification procedure was carried out in two steps at 20ºC. In the first step, embryos were 
placed for 2 minutes in a vitrification solution consisting of 12.5% (v/v) dimethyl sulphoxide (DMSO, 
Sigma) and 12.5% (v/v) ethylene glycol ( EG, Sigma) in DPBS supplemented with 0.2% (w/v) of 
BSA. In the second step, embryos were suspended for 1 minute in a solution of 20% (v/v) DMSO and 
20% (v/v) EG in DPBS supplemented with 0.2% (w/v) of BSA. Then, embryos suspended in 
vitrification medium were loaded into 0.125ml plastic ministraws (IMV, L´Aigle, France) between 
two drops of DPBS separated by air bubbles. Finally, the straws were sealed and plunged directly into 
liquid nitrogen. De-vitrification was performed in two steps, first ministraws were placed to 10 cm 
from vapour nitrogen until  vitrified fraction begin to cristalize (20-30 sec) and, then, submerged into 
a water bath at 20 °C for 10 sec. To remove the vitrification, warmed embryos were introduced into a 
culture dish containing 0.33 M sucrose in DPBS supplemented with 0.2% BSA, after 5 min embryos 
were washed in DPBS for another 5 minutes. Thereafter, 30 de-vitrified embryos were cultured for 48 
hours in Medium 199+20% FBS (Sigma) at 38.5ºC, 5% CO2 and saturated humidity to asses post-
vitrification viability. Twenty-four of them reached to state of hatching blastocyst (80%). 
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Embryo transfer 
The recipient doe was injected intramuscularly with 25IU of eCG 60 hours prior to induce the 
ovulation with an intramuscular injection of 2µg of Buserelin Acetate (Hoechst, S.A.). The transfer 
was performed by mini-midline laparotomy, using previous scar to enter the abdomen. The uterus was 
externalised to allow for ease of access. Seventeen intact de-vitrified embryos were placed in  cornua 





Experiments were carried out in the first four weeks following the above ET. 3ml of blood was taken 
at appropriate intervals during the gestational period to obtain a reproductive profile (βhCG, FSH, LH, 
Testosterone, 17β-Oestradiol and Progesterone). Furthermore, a colour Doppler ultrasound with a 
two-dimensional 7.5MHz (range: 7-10MHz) probe was used to monitor fetal development and 
growth. The protocol has been described already by Chavatte-Palmer et al.23 The ultrasound 
examination was performed from right to left with the probe in the sagittal orientation, following 
localisation of the urinary bladder. The initial scan was performed on Day 5 post-ET with the aim to 
judge whether any fetal sacks were present. Subsequent scans are done at 3-4 day intervals until the 
day of the elective Caesarean section. With respect to measurements, for the fetal sack, they are made 
when the largest surface area appears on the screen. Important for growth, crown-rump length (CRL) 




Recipient #5 was the sole long-term (>30 days) surviving doe out of the cohort of nine. The doe 
showed no adverse effects post-operatively and throughout the recovery period. She was feeding and 
drinking well, with appropriate movement and affect. Following visualization of certain signs 
	   12 
suggesting a receptive doe, embryo transfer was performed on day 89 post-UTn. Vitrified embryos 
were prepared at the same time, with 17 transferred into the cornua of the sole surviving doe by open 
laparotomy and insertion of catheter transmurally (nine into the right and eight in the left cornua). The 
doe began to demonstrate signs of pregnancy, including nesting and an increase in abdominal size 
towards the end of the first gestational week.  
 
D5 scan did not demonstrate a fetal sac. Fetal sac diameter on D9, D13, D16 and D18 was (mm): 
17.3x13.1, 22.1x19.5, 25.2x22.7, and 10.2x6.3 (Figure 2). CRL was only recordable on D9, D13 and 
D16 (mm): 10.2x6.3, 14.3x9.5, and 16.4x15.3 respectively. Subsequent scans on D22 and D25 did not 
demonstrate a fetal sac, which together with the fetal sac diameter was suggestive of resorption. No 
bleeding was witnessed around the cage. The doe’s behaviour was noticed to have returned to pre-
embryo transfer period four days before she was culled. The recipient was sacrificed on D27. 
Necropsy and histopathology confirmed evidence of a gravid uterus and the presence of a gestational 
sac (Figures 3 and 4). 
 
Unfortunately as a result of resistance from the doe, only one blood sample was possible during the 
gestational period. D102 was D13 of the gestational period (Figure 5). Table 2 demonstrates renal, 






Our pregnancy did not result in the birth of a healthy term offspring. However the demonstration of 
pregnancy in this allogeneic model is a central proof of concept of UTn in a rabbit model and thereby 
an essential step in the research toward its clinical application in the human. The study represents only 
the third example of conception and pregnacy following an allogeneic UTn. To date, there has only 
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been one live birth following allogeneic UTn. The animal model was large (sheep), and thus, no live 




The macrovascular patch model functioned in that the uterine graft received an adequate blood supply, 
allowing for implantation and  fetal growth. The renal, hepatic and reproductive profiles were normal 
throughout the post-operative period, during which time the recipient doe was taking daily tacrolimus. 
Its daily routine was also normal, with no adverse characteristics demonstrated with respect to 
behaviour, eating and drinking patterns, movement and fertility induction.  
 
Embryo transfer techniques should be used to transport the already formed embryos into the uterine 
graft after transplantation in order to exclude any events which might compromise the graft. For 
example, it is likely that natural conception would not occur as the fallopian tubes would not be 
functional and if it did occur, it could lead to intra-/extra-uterine ectopic and tubal miscarriages. Some, 
including this team, propose that the Fallopian tubes should not be transplanted as part of an UTn.2,6 
 
One of the key issues concerning UTn is finding a suitable immunosuppressive protocol which 
achieves graft protection from the body’s rejection processes but also does not harm the embryo of the 
fetus. This resorbed pregnancy may therefore be explained by either the potential negative impact of 
tacrolimus on early fetal growth, or by a clinical rejected uterus because of inadequate 
immunosuppression. With regards to the former point, tacrolimus was selected as it is now widely 
used in clinical organ transplantation. It has lower nephrotoxicity, with reports from large studies 
stating fewer episodes of acute rejection compared with the traditional calcineurin inhibitor CsA.24 Its 
mode of action suppresses T-lymphocyte activation via the inhibition of calcineurin-dependent 
interleukin IL-2 production.25 Importantly it can be used after initial induction therapy as a single 
immunosuppressant in liver transplantation,26 and tacrolimus has been used extensively during 
pregnancies in organ transplant recipients (a significant consideration for UTn).27,28 The latest study 
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on the effects of tacrolimus on UTn, evaluated the effects of tacrolimus on the rejection of a 
transplanted rat uterus and on uterine expression of markers of inflammation and implantation.28 Non-
treated uterine grafts showed rejection with necrosis. Tacrolimus-treated transplanted group exhibited 
normal uterine morphology with low numbers of T-lymphocytes in all uteri except in two out of seven 
uteri of the tacrolimus-treated transplant group. Uteri of the non-treated transplanted group showed 
elevated mRNA expression of IL-1a and IP-10 and reduced galectin-1, compared with the tacrolimus-
treated transplanted group. Therefore, tacrolimus monotherapy suppressed rejection of an 
allotransplanted uterus, normalized the expression of IL-1a and IP-10 and prevented T-lymphocyte 
infiltration. The tacrolimus in our experiment did overall decrease the rejection response (Figure 5). 
However, three rejection episodes did occur, with the ultimate episode occurring during pregnancy. 
Despite managing to control the first two (occurring on days 36 and 74), some uterine structural 
damage must have occurred, thus rendering the graft less suitable for carrying a pregnancy until term. 
The third episode on day 102 could have been the final insult which led to miscarriage, most probably 
occurring three days later (Figure 2). It is therefore unlikely that it was the effects of tacrolimus which 
led to intra-uterine death but rather that the rejection response itself was inadequate to protect the graft 
carrying the pregnancy. This could be either because the dose of tacrolimus was inadequate or that an 
additional immunosuppressant, in the form of a monoclonal antibody, should be added. Further such 
experiments are required but should be carried out in a larger-animal model, because of difficulties of 
using a rabbit model. 
 
Advances in immunosuppression as well as original modalities to induce tolerance of a transplanted 
uterus may reduce these problems in the future. The induction of immunological tolerance to a 
transplanted graft offers a novel potential solution to inhibiting immune-mediated graft rejection. 
Tolerance is defined as the specific and permanent absence of an attack or response by the immune 
system to a foreign antigen, which in our case is represented by the uterine graft antigen, without 
immunosuppression.29  It can be classified as either natural which occurs via either a central (in the 
thymus and bone marrow) or peripheral (circulating mature T and B cells) pathway, or acquired. The 
ultimate clinical goal would be for the patient to ‘acquire’ tolerance, both in the non-pregnant and 
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pregnant state, as natural tolerance cannot deal with foreign antigens. This would mean an almost 
complete allo-unresponsiveness to donor cells and therefore a diminished use of immunosuppressants 
and negligible damage to the uterine graft as a result of both the pre-clinical and clinical rejection 
process. Thus, it is important to differentiate between the role of immunosuppressants and tolerance 
modulation in the graft acceptance process. The level of an immunosuppressant administered to a 
patient can indeed portray the state of clinical tolerance, yet the drug does not provide tolerance 
induction in general. In certain cases, immunosuppressants can diminish the overall tolerance effect, 
for example, calcineurin inhibitors which downgrade the action of all T cells, including regulatory T 
cells (Tregs).30 
 
The field of immunomodulation continues to develop, and could lead to the ultimate goal, a post-
transplant world involving no regular immunosuppression medication. Aside from Tregs, 
immunosuppression may also be induced after a single treatment course. For example, T10B9, a 
monoclonal antibody directed against the alpha-beta heterodimer of the T-lymphocyte receptor 
complex, has been used successfully to treat acute cellular rejection in renal transplantation and as an 
immunosuppression induction agent in heart and simultaneous kidney-pancreas transplantation.31 
Kawai et al described combined bone marrow and kidney transplants from HLA single-haplotype 
mismatched living, related donors resulting in induced immunotolerance.32 
 
Unfortunately, pregnant transplant recipients cannot wait for long term results to clearly demonstrate 
superiority of one regimen over the other. This is especially a problem regarding pregnancy outcomes 
among transplant patients. Regardless, if the pregnant transplant recipient has a kidney, heart, lung or 
uterus, it will be impossible to ensure safety to mother and fetus if the goal is a healthy child that 
matures to a healthy adult.  
 
We cautiously predict that from the immunological point of view, the risks to mother and fetus will be 
no different to those faced by renal, hepatic or cardiac transplant patients undergoing pregnancy. The 
patient must be considered as high risk from the beginning of the pregnancy. She should be managed 
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under a multi-disciplinary team, involving in particular a physician specializing in high-risk obstetrics 
and a transplant immunologist. The care pathway would be very similar to any pregnant patient with a 
transplanted organ. Because of the effects of immunosuppressants on the maternal immune system, 
viral serology for cytomegalovirus as well as microbiological cultures of vaginal smears should be 
repeated monthly. Levels of immunosuppressive drugs in the blood should be monitored, thus 
permitting adjustments of drug dose relative to graft function and physiological changes of pregnancy. 
Doppler assessment of the vascular uterine supply as well as anastomosis may be helpful if not 
interesting. Visual inspection of the transplanted cervix would likely provide clinical clues of the 




Despite the end result of the experiment i.e. termination of pregnancy as a result of miscarriage, the 
study represents only the third example of conception and pregnancy following an allogeneic UTn. 
The surgical anatomical macrovascular model was successful. Post-operative recovery was 
uneventful, with no adverse effects recorded. The cause of fetal demise is most likely secondary to 
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Table 1 Immunosuppressant risk categories according to US Food and Drug Administration165  
 
 
Category Drug Animal / Human studies 
A Paracetamol No risk in human studies 
B Corticosteroids 
No risk in animal studies OR 







Fetal risk demonstrated in animal studies BUT no adequate 
and well-controlled studies in humans. 
Drugs can be used if potential benefits outweigh risks. 
D Azathioprine 
Fetal risk demonstrated in human studies. 
In exceptional circumstances, drugs can be used if potential 
benefits outweigh risks. 













Table 2 Renal, hepatic and reproductive profiles from D0 to D102 
 
 UTn 5  
Gestational Age D0 D2 D6 D9 D13 D20 D36 D46 D60 D74 D102 
Sodium 151 141 142 143 142 143 144 144 144 141 141 
Potassium 3.9 4.7 NM 4.3 4.5 3.8 3.8 4.0 NM 4.2 4.4 
Urea 8.9 21.8 12.2 7.6 6.2 6.8 5.8 6.7 7.6 7.2 7.6 
Creatinine 131 115 91 89 82 79 82 91 106 95 95 
AST 40 63 21 14 23 30 22 29 NM 25 36 
ALT 28 71 44 26 17 22 21 27 31 23 19 
ALP 41 21 NM 37 34 34 38 36 42 50 18 
Albumin 57 42 50 49 45 50 51 56 55 56 48 
CRP NA <0.6 <0.6 <0.6 <0.6 <0.6 <0.6 <0.6 <0.6 <0.6 - 
Reproductive profile 
17β-oestradiol 70 47 57 83 90 112 60 102 101 92 45 
LH 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 
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For ranges please, refer to Hewitt et al 
	  




Figure 1 Pregnancy and Uterine Transplantation 2	  
FSH 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 
Testosterone 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 
Progesterone 0.5 0.5 0.5 0.5 0.5 0.6 0.5 0.7 0.5 0.5 15.5 
Immunosuppressant 
Tacrolimus Levels NA NM 2 2 2 2 2 2 2 2 - 
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Figure 3 ‘Uterine Cavity’ on D113 post-UTn (cull of doe) 
 
Uterus containing fetal sac and 
now resorped fetus 
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Figure 4 Products of conception: Chorionic Villi  
 
 
Figure 5 White cell subset levels including those taken during pregnancy 
 
